S*BIO Pte Ltd.(Other News To Note)(Brief article)

S*BIO Pte Ltd., of Singapore, said the FDA has granted orphan drug designation to SB1518, its orally active JAK2 inhibitor for the treatment of myeloproliferative disorder. SB1518 has the potential to interfere with a key mechanism driving the progress of a variety of cancers and other …